Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Current Assets
All assets expected to be converted to cash or used up within one year.
Actuate Therapeutics IncNASDAQ: ACTU
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 100.5% from a year ago
Total current assets stood at $8.52M at the end of Q1 FY2026, up 100.5% from a year earlier and down 37.6% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.
Context
- Total current assets amounted to 95.6% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +100.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 13.64M USD
- Year-over-year change
- +48.2%
- 3-year CAGR
- -12.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.64M | +48.2% |
| FY2024 | 2024-12-31 | 9.21M | +207.4% |
| FY2023 | 2023-12-31 | 3M | -85.4% |
| FY2022 | 2022-12-31 | 20.48M | — |
Total Current Assets vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +100.5% is the 2nd highest of 9, against a peer median of -22.8%.
- Total current assets amounts to 95.6% of total assets for ACTU, versus a peer median of 87.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $500.78M USD | +672.2% | +24.6% | 98.8% | |
| Mar 2026 | $235.89M USD | -13.1% | -7.8% | 63.4% | |
| Mar 2026 | $215.08M USD | -41.3% | -28.4% | 89.6% | |
| Mar 2026 | $134.27M USD | +32.9% | -6.7% | 85.9% | |
| Mar 2026 | CHF 82.68M CHF | -39.6% | -27.6% | 94.6% | |
| Mar 2026 | $57.61M USD | -22.9% | -14.9% | 97.6% | |
| Mar 2026 | $31.84M USD | -51.8% | -36.7% | 27.1% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $16.2M USD | -22.6% | +21.7% | 71.4% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.52M USD | +100.5% | -12.7% | 95.6% |
| Peer median (excluding ACTU) | — | -22.8% | -11.4% | 87.8% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.